Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ROIV Roivant Sciences
7.800+0.210+2.77%
Close
02/03 16:00 ET
7.626-0.174-2.23%
Post Mkt Price 02/03 17:41 ET
High
8.275
Open
7.870
Turnover
71.69M
Low
7.715
Pre Close
7.590
Volume
9.01M
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Roivant Sciences Prices $200 Million Upsized Common Stock Offering
03:21 AM EST, 02/03/2023 (MT Newswires) -- Roivant Sciences (ROIV) said late Thursday it has priced an underwritten public offering of about 26.7 million common shares at $7.50 each for expected gross
Roivant Sciences Prices Upsized Public Offering of 26,666,666 Shares at $7.50 Each >ROIV
Roivant Sciences Expects Gross Proceeds of $200M >ROIV
Roivant Sciences Expects Gross Proceeds of $200M >ROIV
Roivant Sciences Offering Is Expected to Close Feb. 7 >ROIV
Roivant Sciences 26.67M Share Secondary Priced at $7.50
Roivant Sciences Announces Pricing of Upsized Public Offering of Common Shares
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Roivant Sciences (NASDAQ:ROIV) today announced the pricing of an upsized underwritten public offering of 26,666,666 of its common
Roivant Sciences Launches $150 Million Common Stock Offering
Fly Intel: After-Hours Movers
Roivant Launches $150M Stock Offering, Shares Fall
Roivant Sciences Announces $150M Common Shares Offering
Company Overview
More
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.
CEO： Mr. Matthew Gline
Market： NASDAQ
Listing Date： 12/14/2020
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet